Compare Amgen, Inc. (AMGN) vs EHang Holdings Ltd - ADR (EH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs EHang Holdings Ltd - ADR — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while EHang Holdings Ltd - ADR trades at $5.54 (market cap $423.98M). The key difference: Amgen, Inc. is far larger — about 462.6× EHang Holdings Ltd - ADR's market cap, and Amgen, Inc. pays a 2.77% dividend while EHang Holdings Ltd - ADR pays none. Which is the better fit depends on your goals.
| AMGN | EH | |
|---|---|---|
Market Cap | $196.12B | $423.98M |
Sector | Health | Industrials |
52-Week High | $388.16 | $19.99 |
52-Week Low | $271.18 | $5.52 |
Enterprise Value | $241.41B | $363.64M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
EHang Holdings (EH) trades at $5.59, down 3.45% today, with a bearish technical signal from moving averages. The company reported Q1 2026 revenue of $418M, flat year-over-year but sharply lower sequentially due to delivery timing. Despite a high gross margin of 61.53%, net losses persist with a -77.56% margin. Cash flow improved in 2024 but reversed negative in 2025. Recent news highlights volatility, including an 18% surge on June 15, 2026, followed by concerns over Q1 sales missing forecasts.
The outlook remains speculative with significant execution risks amid ongoing losses, though analyst consensus suggests moderate upside to a $6.97 target. Investment opportunity hinges on commercial scaling of eVTOL operations, but high cash burn and competitive pressures pose substantial risks. Sentiment is divided, with 40% sell ratings reflecting skepticism over near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About EHang Holdings Ltd - ADR
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →
